scout
News|Videos|April 16, 2025

Safety and Efficacy of Luspatercept for the Treatment of Anemia in Patients with Myelofibrosis: Results From the ACE-536-MF-001 Study

Dr. Aaron Gerds presents results from the Phase 2 ACE-536-MF-001 study, demonstrating that luspatercept improves anemia in patients with myelofibrosis—with or without transfusion dependence—and shows encouraging activity when combined with ruxolitinib, with a manageable safety profile and no new safety signals.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME